clinical trial · NCT06566820
Continuation Protocol for Obstructive Sleep Apnea (OSA)
Apnimed·phase3·enrolling by invitation·n = 1,280
OSAAroxybutynin and Atomoxetine
brief summary
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.
started
Jul 3, 2024
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
May 13, 2025
official title
A Phase 3 Open Label Continuation Protocol of a Fixed Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol